Clinical trial NCT01309438: A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
Official title: An Open-Label Study to Estimate the Effect of Multiple Doses of Erythromycin on the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With Renal Impairment and Normal Renal Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Renal Insufficiency
Keywords: Healthy
Renal Insufficiency
Rivaroxaban (BAY 59-7939, JNJ-39039039)
Erythromycin
Pharmacokinetic
Pharmacodynamic
Lead sponsor: Janssen Research & Development, LLC
Sponsor class: INDUSTRY
Collaborators: name: Bayer
First posted: 2011-03-07
Enrollment: 29
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics and pharmacodynamics of rivaroxaban administered to study participants with normal renal function.

Detailed description: This is an open-label study (participants and the study physician \[Investigator\] will know the identity of the assigned treatments) to compare the pharmacokinetics (PK) (how the drugs are absorbed in the body) and pharmacodynamics (PD) (the actions or effects of drugs on the body) of rivaroxaban in study participants with mild or moderate renal impairment (reduced kidney function) receiving multiple doses of erythromycin, to the PK and PD of a single dose of rivaroxaban administered alone in study participants with normal renal function. The study drugs used will be rivaroxaban, a drug that acts to thin the blood to prevent the formation of blood clots, and erythromycin, an antibiotic used to treat patients with bacterial infections. Study participants with normal renal function will receive Treatment A (1 oral \[by mouth\] dose 10 mg rivaroxaban for 1 day) and Treatment C (500 mg oral erythromycin 3x a day (t.i.d.) on Days 1-6 + 1 oral dose of 10 mg rivaroxaban on Day 5). Study participants with mild and moderate renal impairment will receive Treatment A, Treatment B (500 mg oral erythromycin t.i.d. on Days 1-6 + 1 oral dose of 5 mg rivaroxaban Day 5), and Treatment C. Treatments A, B, and C will be separated by up to 14 days.

Eligibility criteria: Inclusion Criteria:

* Have a body mass index (BMI) between 18 and 38 kg/m2, inclusive
* Have a body weight of not less than 50 kg and have been characterized as having normal renal function (creatinine clearance \[CLCR\] \> 80 mL/min), mild renal impairment (CLCR 50-79 mL/min) or moderate renal impairment (CLCR 30-49 mL/min)
* Study participants with renal impairment should have stable renal disease as determined by the Investigator

Exclusion Criteria:

* History of current clinically significant medical illness or any other illness that the Investigator considers should exclude the study participant or that could interfere with the interpretation of the study results
* Additional exclusion criteria for study participants with normal renal function include: diastolic blood pressure \> 95 mm Hg and/or systolic blood pressure \> 150 mm Hg)
* Additional exclusion criteria for study participants with renal impairment include: diastolic blood pressure \> 100 mm Hg and/or systolic blood pressure \> 170 mm Hg, other routine laboratory parameters \> upper limit of normal which could not be explained by the underlying renal disease unless judged to be clinically unimportant by the investigator, have acute renal failure, or be a recipient of transplanted organs
* Have severe renal impairment (CLCR \< 30 mL/min)

Primary outcomes:
measure: Rivaroxaban plasma concentrations
timeFrame: Up to Day 7 of Treatment Period 3
measure: Erythromycin plasma concentrations
timeFrame: Up to Day 7 of Treatment Period 3
measure: Rivaroxaban urine concentrations
timeFrame: Up to Day 7 of Treatment Period 3
Secondary outcomes:
measure: The number of patients with adverse events reported
timeFrame: Up to 48 hours after Day 7 of Treatment Period 3
measure: Coagulation tests (prothrombin time [PT] and activated partial thromboplastin time [aPTT])
timeFrame: Up to Day 6 of Treatment Period 3
Other outcomes:
Locations:
city: Orlando
country: United States
state: Florida
city: Minneapolis
country: United States
state: Minnesota
city: St. Paul
country: United States
state: Minnesota
city: Knoxville
country: United States
state: Tennessee
Study officials:
affiliation: Janssen Research & Development, LLC
name: Janssen Research & Development, LLC Clinical Trial
role: STUDY_DIRECTOR
References: